alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
##### 



Exhibit 10.4
 
 Zila, Inc.       Nutraceuticals | Pharmaceuticals | Biotechnology
 www.zila.com
  
   1. Title.
 2. Start Date.
 3. Reporting Structure.
 4. Responsibilities.
 5. Base Salary.
 6. Auto allowance.
 7. Eligibility for Performance Bonuses.




---



##### 



8. Stock Options.
 9. Insurance.
 10. Paid Time Off.
 11. Other Benefits.
 12. Relocation Expenses.




---



##### 



13. Board of Directors Observation Rights.
 14. At-Will Employment.
 15. Severance Pay.
 15.1 Termination Triggering Right to Severance Pay.
 15.2 Release Required.




---



##### 



15.3 No Other Right to Severance Pay.
 15.4 Timing of severance pay.
 15.5 Cessation of Severance Pay.
 16. Cooperation in Dispute Resolution.
 17. Applicable Law. conflict-of-




---



##### 



18. Severability.
 19. Other agreements.
    
 Statement of Acceptance:
  Dated: 5/22/06
    
    /s/ Frank J. BellizziFrank J. Bellizzi
<PAGE>
 
                                                                    EXHIBIT 24.1

                        CONSENT OF INDEPENDENT AUDITORS

 
Shareholders and Board of Directors
Sizeler Property Investors, Inc.:
 
  We consent to incorporation by reference in the registration statement (No.
33-76134) on Form S-3 of Sizeler Property Investors, Inc. of our report dated
February 1, 1996, relating to the consolidated balance sheet of Sizeler
Property Investor, Inc. and subsidiaries as of December 31, 1995 and the
related consolidated statements of income, shareholders' equity, and cash flows
for the year then ended, and the related financial statement schedules, which
report appears in the December 31, 1995, annual report on Form 10-K of Sizeler
Property Investors, Inc.
 
                                          KPMG Peat Marwick LLP
 
New Orleans, Louisiana
March 27, 1996
<TABLE> <S> <C>


<ARTICLE>                                            5
<LEGEND>
                           This schedule contains summary financial  information
                           extracted from Venture World Ltd.  September 30, 1997
                           financial statements and is qualified in its entirety
                           by reference to such financial statements.
</LEGEND>

<CIK>                                0000826683
<NAME>                               Venture World Ltd.

       
<S>                                  <C>
<PERIOD-TYPE>                        9-MOS
<FISCAL-YEAR-END>                                      DEC-31-1997
<PERIOD-END>                                           SEP-30-1997

<CASH>                                                 0
<SECURITIES>                                           0
<RECEIVABLES>                                          0
<ALLOWANCES>                                           0
<INVENTORY>                                            0
<CURRENT-ASSETS>                                       0
<PP&E>                                                 0
<DEPRECIATION>                                         0
<TOTAL-ASSETS>                                         0
<CURRENT-LIABILITIES>                                  1,300
<BONDS>                                                0
<PREFERRED-MANDATORY>                                  0
<PREFERRED>                                            0
<COMMON>                                               5,000
<OTHER-SE>                                             (6,300)
<TOTAL-LIABILITY-AND-EQUITY>                           0
<SALES>                                                0
<TOTAL-REVENUES>                                       0
<CGS>                                                  0
<TOTAL-COSTS>                                          0
<OTHER-EXPENSES>                                       0
<LOSS-PROVISION>                                       0
<INTEREST-EXPENSE>                                     0
<INCOME-PRETAX>                                        0
<INCOME-TAX>                                           0
<INCOME-CONTINUING>                                    0
<DISCONTINUED>                                         0
<EXTRAORDINARY>                                        0
<CHANGES>                                              0
<NET-INCOME>                                           0
<EPS-PRIMARY>                                          .00
<EPS-DILUTED>                                          .00
        


</TABLE>
EXHIBIT 32
                                   ----------

                  CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
                       PURSUANT TO 18 U.S.C. SECTION 1350


In  connection  with  the  accompanying  Quarterly  Report  on  Form  10-QSB  of
NanoPierce  Technologies,  Inc. for the quarter ended March 31, 2004, I, Paul H.
Metzinger,  President  and  Chief  Executive Officer of NanoPierce Technologies,
Inc.,  hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section  906  of  the  Sarbanes-Oxley  Act  of  2002,  to  my  knowledge,  that:

     a)   such  Quarterly Report on Form 10-QSB of NanoPierce Technologies, Inc.
          for  the  quarter  ended  March  31,  2004,  fully  complies  with the
          requirements  of section 13(a) or 15(d) of the Securities Exchange Act
          of  1934;  and

     b)   the  information  contained in such Quarterly Report on Form 10-QSB of
          NanoPierce  Technologies,  Inc.  for the quarter ended March 31, 2004,
          fairly presents, in all material respects, the financial condition and
          results  of  operations  of  NanoPierce  Technologies,  Inc.





                                   /s/Paul H. Metzinger
                                   ----------------------------------
                                   Paul H. Metzinger, Chief Executive
                                   Officer & President


Date:  May 17, 2004



               A  signed  original of this written statement required by Section
               906  has  been provided to NanoPierce Technologies, Inc. and will
               be retained by NanoPierce Technologies, Inc. and furnished to the
               Securities  and  Exchange  Commission  or its staff upon request.


<PAGE>
```

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3613 Introduced in House (IH)]

<DOC>

117th CONGRESS
  1st Session
                                H. R. 3613

 To designate the facility of the United States Postal Service located 
  at 202 Trumbull Street in Saint Clair, Michigan, as the ``Corporal 
            Jeffrey Robert Standfest Post Office Building''.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 28, 2021

 Mrs. McClain (for herself, Mr. Bergman, Mr. Huizenga, Mr. Meijer, Mr. 
Moolenaar, Mr. Upton, Mr. Walberg, Mr. Levin of Michigan, Ms. Stevens, 
and Mrs. Dingell) introduced the following bill; which was referred to 
                 the Committee on Oversight and Reform

_______________________________________________________________________

                                 A BILL

 
 To designate the facility of the United States Postal Service located 
  at 202 Trumbull Street in Saint Clair, Michigan, as the ``Corporal 
            Jeffrey Robert Standfest Post Office Building''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CORPORAL JEFFREY ROBERT STANDFEST POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at 202 Trumbull Street in Saint Clair, Michigan, shall be known 
and designated as the ``Corporal Jeffrey Robert Standfest Post Office 
Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Corporal 
Jeffrey Robert Standfest Post Office Building''.
                                 <all>
```
#### UNITED STATES of America, Appellee, v. Gerardo G. SALINAS, Appellant.

No. 10-2329.

United States Court of Appeals, Eighth Circuit.

Submitted: Dec. 20, 2010.

Filed: Dec. 23, 2010.

*79Richard D. Westphal, Assistant U.S. Attorney, U.S. Attorney’s Office, Davenport, IA, for Appellee.

Anne M. Laverty, Mullin & Laverty, Cedar Rapids, IA, for Appellant.

Gerardo G. Salinas, Leavenworth, KS, pro se.

Before LOKEN, MURPHY, and BENTON, Circuit Judges.

PER CURIAM.

Gerardo Salinas appeals the sentence the district court1 imposed after he pleaded guilty to conspiracy to distribute a mixture or substance containing methamphetamine. Counsel has filed a brief under *Anders v. California,*386 U.S. 738, 87 S.Ct. 1396, 18 L.Ed.2d 493 (1967), arguing that the sentence is unreasonable because the court gave undue weight to Salinas’s prior convictions. In a supplemental pro se brief, Salinas challenges the presentence report’s (PSR’s) calculation of his criminal history score and the description of his prior felony convictions; argues that he does not deserve career-offender status; and asserts that the court stenographer inaccurately transcribed his allocution testimony. For the following reasons, we affirm.

First, we conclude that Salinas forfeited any challenge to the PSR’s recitation of the facts and its recommendations as to his career-offender status and criminal history score. Salinas resolved his objections to the PSR upon reaching an agreement with the government, and he advised the district court that the PSR, as amended to reflect his agreement with the government, accurately stated the facts and correctly calculated his Guidelines range. *See United States v. Olano,*507 U.S. 725, 733-34, 113 S.Ct. 1770, 123 L.Ed.2d 508 (1993). In any event, exercising our discretion to review for plain error, *see United States v. Wallace,*408 F.3d 1046, 1048-49 (8th Cir.2005) (per curiam), we find none. Second, Salinas does not explain how his allegedly inaccurately transcribed allocution testimony is a basis to challenge his sentence in this direct criminal appeal. And third, the district court’s sentence is not unreasonable. *See United States v. Feemster,*572 F.3d 455, 461 (8th Cir.2009) (en banc) (standard of review; describing factors that demonstrate procedural error).

*80Finally, having reviewed the record independently under *Penson v. Ohio,*488 U.S. 75, 80, 109 S.Ct. 346, 102 L.Ed.2d 300 (1988), we have found no nonfrivolous issues for appeal. Accordingly, we affirm the district court’s judgment.

1

. The Honorable John A. Jarvey, United States District Judge for the Southern District of Iowa.
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussion could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Allergy and Infectious Diseases Special Emphasis Panel                    

*Date:*                         February 27, 2001.                    

*Time:*                         8:30 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         Bethesda Marriott Hotel, Congressional Salon Conference Room, 5100 Pook's Hill Road, Bethesda, MD.                    

*Contract Person:*                         Paula S. Strickland, PhD., Scientific Review Administrator, Scientific Review Program, Division of Extramural Activities, NIAID, NIH, Solar Building, Room 4C02, 6003 Executive Boulevard MSC 7610, Bethesda, MD 20892-7610, 301-402-0643.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, Transplantation, Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: February 2, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-3466 Filed 2-09-01; 8:45 am]

BILLING CODE 4140-01-M
<TABLE> <S> <C>

<ARTICLE>           5
<MULTIPLIER>        1,000
       
<S>                                     <C>         
<PERIOD-TYPE>                           12-MOS      
<FISCAL-YEAR-END>                       Dec-31-1996 
<PERIOD-START>                          Jan-01-1996 
<PERIOD-END>                            Dec-31-1996 
<CASH>                                        3,964 
<SECURITIES>                                      0 
<RECEIVABLES>                                 4,745 
<ALLOWANCES>                                  1,626 
<INVENTORY>                                       0 
<CURRENT-ASSETS>                              7,617 
<PP&E>                                          323 
<DEPRECIATION>                                    0 
<TOTAL-ASSETS>                                7,940 
<CURRENT-LIABILITIES>                         3,062 
<BONDS>                                           0 
<COMMON>                                      5,802 
<PREFERRED-MANDATORY>                             0 
<PREFERRED>                                       0 
<OTHER-SE>                                        0 
<TOTAL-LIABILITY-AND-EQUITY>                  7,940 
<SALES>                                           0 
<TOTAL-REVENUES>                             24,003 
<CGS>                                             0 
<TOTAL-COSTS>                                15,527 
<OTHER-EXPENSES>                              9,808 
<LOSS-PROVISION>                                 50 
<INTEREST-EXPENSE>                             (165)
<INCOME-PRETAX>                              (1,217)
<INCOME-TAX>                                   (137)
<INCOME-CONTINUING>                          (1,080)
<DISCONTINUED>                                    0 
<EXTRAORDINARY>                                   0 
<CHANGES>                                         0 
<NET-INCOME>                                 (1,080)
<EPS-PRIMARY>                                 (0.11)
<EPS-DILUTED>                                 (0.11)
        

</TABLE>
2014-0388.

#### Zeune v. Pineda.

In Habeas Corpus. On petition for writ of habeas corpus of Rodney D. Zeune. Sua sponte, cause dismissed.

O’Connor, C.J., and Pfeifer, O’Donnell, Lanzinger, Kennedy, and O’Neill, JJ., concur.

French, J., not participating.
Michigan Supreme Court

Lansing, Michigan

Bridget M. McCormack

, Chief Justice

David F. Viviano,

Chief Justice Pro Tem

Stephen J. Markman

Brian K. Zahra

Richard H. Bernstein

Elizabeth T. Clement

Megan K. Cavanagh,

Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

July 2, 2019

a0624 

# Order

Clerk July 2, 2019

158527

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff

- Appellee,

v SC: 158527

COA: 344498

Shiawassee CC: 2017

- 009737

- FH

DANIEL PATRICK McCONNELL,

Defendant

- Appellant.

____________________________________/

On order of the Court, the application for leave to appeal the August 15, 2018

order of the Court of Appeals is considered and, pursuant to MCR 7.305(H)(1), in lieu of

granting leave to appeal, we REMAND this case to the Court of Appeals for

consideration as on leave granted.
<TABLE> <S> <C>

<ARTICLE> 5
<CIK> 0000827164
<NAME> EXHIBITRONIX, INC.
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-END>                               MAR-31-1998
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                       0
<CURRENT-LIABILITIES>                            3,324
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         6,428
<OTHER-SE>                                     (9,752)
<TOTAL-LIABILITY-AND-EQUITY>                         0
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                    3,239
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (3,239)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                            (3,239)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (3,239)
<EPS-PRIMARY>                                    (.00)
<EPS-DILUTED>                                        0
        

</TABLE>
EXHIBIT 11

                          NANOPIERCE TECHNOLOGIES, INC.
                        COMPUTATION OF NET LOSS PER SHARE


                                                  2002          2001

Net loss                                     $ (1,018,725)     (996,320)
                                             =============  ============
Weighted average number of
  common shares outstanding                    57,643,545    55,701,398

Common equivalent shares
  representing shares issuable
  upon exercise of outstanding
  options and warrants                                  -             -
                                             -------------  ------------
                                               57,643,545    55,701,398
                                             =============  ============

 Net loss per share, basic and diluted       $       (.02)         (.02)
                                             =============  ============


Stock options and warrants are not considered in the calculations as the impact
of the potential common shares (10,927,661 shares at September 30, 2002 and
9,202,661 shares at September 30, 2001) would be to decrease net loss per share.
The potential common shares at September 30, 2002 do not include any additional
shares that may be due under the financing agreement which is the subject of a
suit described in the notes to the condensed financial statements.


<PAGE>
Exhibit 5.10

CONSENT OF AMC CONSULTANTS PTY. LTD.

Reference is made to the Annual Report on Form 40-F for the
year ended December 31, 2006 (the Annual Report) of New Gold Inc. (the Company), filed with the U.S. Securities and Exchange Commission.

We hereby consent to the references to our name under the heading General Development of the Business  Business of New Gold  Three Year History in the Companys Annual Information Form and
to all other references to our name included or incorporated by reference in the Annual Report.



|                          |  |                 |  | 
|------------------------- |  | --------------- |  | 
|AMC CONSULTANTS PTY. LTD.
|                          |  |                
|By:                       |  | /s/ Mike Thomas |  | 
|Name:                     |  | Mike Thomas     |  | 
|Title:                    |  | MAusIMM(CP)     |  | 

March 29, 2007
[Federal Register Volume 66, Number 4 (Friday, January 5, 2001)]
[Notices]
[Page 1146]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-333]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


National Institutes of Medicine; Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be open to the public as indicated below, with 
attendance limited to space available. Individuals who plan to attend 
and need special assistance, such as sign language interpretation or 
other reasonable accommodations, should notify the Contact Person 
listed below in advance of the meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6). Title 5 
U.S.C., as amended. The journals as potential titles to be indexed by 
the National Library of Medicine and the discussions could disclose 
confidential trade secrets of commercial property such as patentable 
material, and personal information concerning individuals associated 
with the journals as potential titles to be indexed by the National 
Library of Medicine, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

    Name of Committee: Literature Selection Technical Review 
Committee.
    Date: February 8-9, 2001.
    Open: February 8, 2001, 9am to 11am.
    Agenda: Administrative Reports and Program Developments.
    Place: National Library of Medicine, Board Room Bldg 38, 2E-09, 
8600 Rockville Pike, Bethesda, MD 20894.
    Closed: February 8, 2001, 11 am to 5 pm.
    Agenda: To review and evaluate journals as potential titles to 
be indexed by the National Library of Medicine.
    Place:National Library of Medicine, Board Room Bldg 38, 2E-09, 
8600 Rockville Pike, Bethesda, MD 20894.
    Closed: February 9, 2001, 8:30 am to 2 pm.
    Agenda: To review and evaluate journals as potential titles to 
be indexed by the National Library of Medicine.
    Place: National Library of Medicine, Board Room Bldg 38, 2E-09, 
8600 Rockville Pike, Bethesda, MD 20894.
    Contact Person: Sheldon Kotzin, BA, Chief, Bibliographic 
Services Division, Division of Library Operations, National Library 
of Medicine, 8600 Rockville Pike, Bldg 38A/Room 4N419, Bethesda, MD 
20894.

(Catalogue of Federal Domestic Assistance Program Nos. 93.879, 
Medical Library Assistance, National Institutes of Health, HHS)

    Dated: December 27, 2000.
Anna P. Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 01-333 Filed 1-4-01; 8:45 am]
BILLING CODE 4140-01-M